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Objectives: To investigate stakeholder perspectives on how patient preference studies 
(PPS) should be designed and conducted to allow for inclusion of patient preferences in 
decision-making along the medical product life cycle (MPLC), and how patient preferences 
can be used in such decision-making.
Methods: Two literature reviews and semi-structured interviews (n = 143) with healthcare 
stakeholders in Europe and the US were conducted; results of these informed the design 
of focus group guides. Eight focus groups were conducted with European patients, 
industry representatives and regulators, and with US regulators and European/Canadian 
health technology assessment (HTA) representatives. Focus groups were analyzed 
thematically using NVivo.
Results: Stakeholder perspectives on how PPS should be designed and conducted 
were as follows: 1) study design should be informed by the research questions and patient 
population; 2) preferred treatment attributes and levels, as well as trade-offs among 
attributes and levels should be investigated; 3) the patient sample and method should 
match the MPLC phase; 4) different stakeholders should collaborate; and 5) results from 
PPS should be shared with relevant stakeholders. The value of patient preferences in 
decision-making was found to increase with the level of patient preference sensitivity of 
decisions on medical products. Stakeholders mentioned that patient preferences are hardly 
used in current decision-making. Potential applications for patient preferences across 
industry, regulatory and HTA processes were identified. Four applications seemed most 
promising for systematic integration of patient preferences: 1) benefit-risk assessment 
by industry and regulators at the marketing-authorization phase; 2) assessment of major 
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contribution to patient care by European regulators; 3) cost-effectiveness analysis; and 4) 
multi criteria decision analysis in HTA.
Conclusions: The value of patient preferences for decision-making depends on the level 
of collaboration across stakeholders; the match between the research question, MPLC 
phase, sample, and preference method used in PPS; and the sensitivity of the decision 
regarding a medical product to patient preferences. Promising applications for patient 
preferences should be further explored with stakeholders to optimize their inclusion in 
decision-making.
Keywords: patient preferences, medical products, decision-making, health technology assessment, marketing 
authorization
highLighTS
- Collaboration among stakeholders in patient preference 
studies (PPS) improves value and acceptance;
- The patient sample and method should match the 
medical product life cycle (MPLC) phase;
- The preference method should be matched to the 
research question and patient population;
- Patient preference sensitivity of decisions regarding 
medical products impacts the value of PPS;
- Applications have to be further explored to allow for 
systematic use of PPS results in MPLC decision-making.
inTRODUCTiOn
Patient preference information is defined by the United States, 
(US) Food and Drug Administration (FDA) as “qualitative 
or quantitative assessments of the relative desirability or 
acceptability to patients of specified alternatives or choices among 
outcomes or other attributes that differ among alternative health 
interventions” (FDA, 2016). Patient preference information, or 
patient preferences, reflects what treatment attributes matter to 
patients, how much these matter to patients and how patients 
make trade-offs between treatment attributes. Patient preferences 
can be estimated through the conduct of patient preference 
studies (PPS) using preference exploration (qualitative) or 
elicitation (quantitative) methods. Preference exploration 
methods can be defined as “qualitative methods that collect 
descriptive data through participant or phenomenon observation, 
and examine the subjective experiences and decisions made by 
participants” (Soekhai et al., 2019). Examples of preference 
exploration methods include semi-structured interviews and 
focus groups. Preference elicitation methods can be defined 
as “quantitative methods collecting quantifiable data that can 
be reported through statistical inferences or analysis” (Soekhai 
et al., 2019). Examples of preference elicitation methods include 
discrete choice experiments (DCE), analytical hierarchy process 
(AHP), and standard gamble. While health preference research 
has existed for over 40 years, the use of PPS in decision-making 
along the lifecycles of drugs and medical devices (called the 
medical product lifecycle; MPLC) is limited but gaining attention 
(Craig et al., 2017).
As with the adoption of all new concepts according to 
Roger's Diffusion of Innovation Theory (Barrow and Toney-
Butler, 2019), the implementation of patient preferences in 
decision-making depends on stakeholders' understanding 
and acceptance of patient preferences as well as how this new 
concept can be put into practice. Important stakeholders 
in this context are patients as they are the ones potentially 
participating in PPS and the ones affected by the decisions that 
can be informed with the study results. The pharmaceutical 
and medical device industry is another important stakeholder 
as they are the potential sponsors of PPS; additionally, 
PPS's results may alter the course of development of their 
products. Last but not least, regulators and HTA bodies and 
payers will be  confronted with the findings of PPS during 
their assessments.
Stakeholders seem to agree on the potential value of patient 
preferences in decision-making along the MPLC (de Bekker-
Grob et al., 2017). Patient preferences are found to provide 
additional information on medical products, such as insights 
into the relative importance to patients of clinical outcomes and 
safety issues. Moreover, they can lead to more relevant, well-
informed, transparent, publically trusted, and patient-centric 
decisions (van Overbeeke et al., 2019). While there seems to be 
agreement on the value of PPS, there is a lack of guidance on 
how to conduct PPS aiming to inform decision-making and on 
how patient preferences can be used in assessments and decision-
making, possibly explaining the limited use of these studies (van 
Overbeeke et al., 2019).
The aim of this study was to investigate stakeholder 
perspectives on how PPS should be designed and conducted to 
allow for inclusion of patient preferences in decision-making 
along the MPLC; moreover, this study investigates how patient 
preferences can be used in such decision-making.
MeThODS
Multi-Method Design
This study was conducted in the context of the “Patient 
Preferences in Benefit-Risk Assessments during the Drug 
Life Cycle” (PREFER) project. The PREFER project aims 
“to strengthen patient-centric decision-making throughout the 
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life cycle of medicinal treatments by developing expert and 
evidence-based recommendations on how patient preferences 
should be assessed and inform decision-making” (de Bekker-
Grob et al., 2017). Two literature reviews and 143 interviews 
with healthcare stakeholders in Europe and the US were 
conducted (Figure 1) to identify stakeholders' needs, factors 
influencing the value of PPS for decision-making, and 
potential applications of patient preferences along the MPLC. 
Methods and results of literature reviews have been published 
elsewhere (Janssens et al., 2019; van Overbeeke et al., 2019), as 
well as those of the interviews (Janssens et al., 2019; Whichello 
et al., 2019). Several topics remained unanswered and group 
discussions were deemed necessary to provide more insight 
and to give further direction on the potential implementation 
of patient preferences in the MPLC.
Design of Focus group guides
Focus group guides (Supplementary Material I) were designed 
with patients, industry representatives, regulators and HTA 
representatives to include topics on which opinions differed during 
the interview phase or deeper understanding was needed. Selected 
patient focus group topics were: important treatment attributes, 
preferred designs of PPS, facilitators and barriers for participating in 
PPS, and data management. Selected topics for industry, regulatory 
and HTA focus groups included: representativeness of the patient 
sample, use of patient preferences, roles of different parties involved 
in PPS and data management in PPS. Before these topics were 
discussed, the definition of patient preferences and an example of a 
PPS were debated with participants.
Participant Recruitment
A total of eight focus groups of 3–10 participants each were 
conducted (Figure 1). Four patient focus groups were conducted 
in Europe, across four disease areas that vary in prevalence, level 
of unmet need, chronicity, and cause (Table 1). In addition, four 
FigURe 1 | Methods used in the multi-method design. First, two 
literature reviews were performed to identify 1) factors and situations 
that influence the value of patient preference studies (PPS) in decision-
making along the MPLC (van Overbeeke et al., 2019), and 2) the potential 
roles, expectations, concerns and requirements associated with using 
patient preferences (Janssens et al., 2019). Second, interviews (n = 
143) with different healthcare stakeholders were held to address the 
same research questions (Whichello et al., 2019; Janssens et al., 2019). 
Lastly, focus groups (n = 8) were conducted to discuss topics related to 
the design, conduct and use of PPS for which opinions of interviewees 
differed or deeper understanding was needed. Abbreviations: HTA, Health 
Technology Assessment; N, number of interviews/focus groups; n, number 
of participants. 
TABLe 1 | Patient and caregiver demographics, clinical information and health literacy
Characteristics Patients and caregivers  
(n = 25)
n %
Sex
 Females 10 40
 Males 15 60
Age, years
 18-24 0 0
 25-39 1 4
 40-60 9 36
 > 60 15 60
Country
 United Kingdom 4 16
 Italy 8 32
 Romania 10 40
 Sweden 3 12
Education
 No diploma 4 16
 High school 11 44
 Bachelor's degree 9 36
 Master's degree 0 0
 PhD 1 4
Stakeholder group
 Patient 22 88
 Caregiver 2 8
 Patient and caregiver 1 4
Disease area
 Neuromuscular disorders 4 16
 Lung cancer 8 32
 Cardiovascular diseases 10 40
 Rheumatoid arthritis 3 12
Years since diagnosis
 < 1 2 8
 1-3 8 32
 4-10 5 20
 > 10 10 40
Health literacy
 Adequate health literacy 20 80
 Inadequate health literacy 5 20
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stakeholder-specific focus groups were held with European industry 
representatives, European regulators, US regulators, and European 
and Canadian HTA representatives, respectively. Participants 
were recruited via patient organizations, hospitals, the European 
Federation of Pharmaceutical Industries and Associations (EFPIA), 
the European Medicines Agency (EMA), the FDA, and the HTA 
advisory group of PREFER. Participants were selected through 
purposive sampling, on the basis of their experiences and expertise. 
Focus groups with regulators specifically included experts on drugs, 
biologics, advanced therapies, orphan drugs, medical devices, and 
patient engagement. In the industry focus group, participants were 
included from research and development, regulatory affairs, market 
access, and patient engagement departments.
Conduct
Patient focus groups were conducted face-to-face in the native 
language of the patients and others - industry, regulatory and HTA 
focus groups – via teleconferences in English, between September 
2017 and April 2018. Patients were asked to fill in a demographics 
survey, including questions on their disease and treatment 
history, as well as health literacy (Table 1). Health literacy was 
assessed using the three health literacy screening questions of 
Chew et  al. (2008), an instrument “based on an individual's 
level of self-reported difficulty with understanding information or 
performing reading tasks they encounter in the health care setting” 
(Chew et al., 2008). Focus groups lasted between 45 min and 2 h 
and were recorded, transcribed verbatim, and pseudonymized. 
Non-English transcripts were translated to English.
Analysis
Demographic characteristics were analyzed using descriptive 
statistics. Health literacy scores were calculated (Chew et al., 
2008; Fransen et al., 2011). Thematic analysis of the focus 
group transcripts, as described by Howitt (Howitt, 2016), 
was performed by two researchers (EO and RJ) to minimize 
variability of interpretation (full analysis plan available in 
Supplementary Material II). The data were investigated for 
patterns, consensuses, and critical observations across focus 
groups, which resulted in the creation of thematic 'codes'. First, the 
researchers familiarized themselves with the content of the focus 
groups by moderating or assisting the focus groups and reading 
the transcripts. Familiarization resulted in the establishment of 
an overview of the collected data, and the researchers became 
aware of key themes and concepts. Subsequently, the researchers 
independently identified topics throughout the transcripts and 
afterwards agreed upon a list of initial themes. The researchers 
reread the transcripts of the focus groups and formulated a list of 
final themes. The text of the transcripts was organized by applying 
the themes using NVivo qualitative data analysis software by 
QRS International Pty Ltd Version 12, 2018. Sections of text that 
corresponded to a theme were indexed, and placed in charts 
with headings reflecting these themes. These charts were then 
analyzed and interpreted for common attitudes and opinions of 
the participants, with comparisons being made between focus 
groups. Definitions were given to themes (Supplementary 
Material III) and the results were described.
ReSULTS
Results were analyzed per stakeholder group and subsequently 
grouped per theme. Codes following quotations refer to 
participants' characteristics: CA, caregiver; CAN, Canada; CVD, 
cardiovascular disease; EU, Europe; HTA, health technology 
assessment representative; IN, industry representative; LC, lung 
cancer; DM, myotonic dystrophy; PA, patient; RA, rheumatoid 
arthritis; RE, regulator; US, United States.
Design and Conduct of Patient 
Preference Studies
Research Questions
For PPS to be valuable for decision-making, industry and 
regulatory representatives mentioned that such studies should 
investigate research questions related to trade-offs between 
benefits and risks, and between benefits and administration 
attributes. Administration attributes of interest included drug 
formulation, administration frequency, time investment and 
place of administration (e.g. home vs. hospital). These trade-offs 
were found to be informative of the risks and administration 
inconveniences patients would tolerate. HTA representatives, 
and also regulators, were interested in what clinical endpoints 
and other attributes patients prefer. HTA representatives stated 
that if they would know what outcomes patients prefer, they 
could assess whether treatments fulfill these needs. In addition, 
regulators would like PPS to provide insights on the burden of 
disease and were interested in methodological research questions 
related to PPS, e.g. how results from different methods compare 
in the same population and how results from different samples 
differ, including samples from different countries.
Representativeness of Participants
All stakeholders were asked who should participate in PPS. 
CVD, and RA patients agreed that patients with different 
disease and treatment experiences should participate and that 
patients should not be excluded based on age, education or 
profession. CVD and DM participants and HTA representatives 
suggested to explore caregiver preferences instead of patient 
preferences in some specific cases: when patients have impaired 
cognitive function or in case patients cannot be asked about 
their preferences. Moreover, MD participants mentioned 
that including severely affected MD patients in a PPS might 
be problematic in cases where MD patients do not accept 
their illness and asking about their preferences would give a 
wrong impression: “because you have put them under pressure 
… you make them uncomfortable so you have not got the right 
response” (CA1_UK_MD). HTA representatives emphasized 
that if caregiver preferences are submitted, it should be justified 
why patient preferences were not explored. One RA and one 
DM patient also suggested that the patient sample should be 
representative of the patient population.
Industry and regulatory representatives mentioned that the 
representativeness requirements for the sample depend on the 
MPLC phase, the methods used, and the claimed indication. 
While for earlier MPLC phases industry representatives 
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advocated for a very diverse sample including different 
countries and cultures, in later phases samples should be 
representative of the international or national population 
for which a decision needs to be made. Moreover, according 
to industry and regulatory representatives, in qualitative 
studies representativeness would be less important than in 
quantitative studies. In industry, regulatory and HTA focus 
groups it was agreed that quantitative PPS samples should be as 
representative as possible of the patient population to allow for 
generalization of results. Non-representativeness was stated to 
lead to non-acceptance of the data by regulators. The meaning 
of a representative sample was further discussed; industry, 
regulatory and HTA representatives mentioned that the sample 
should be representative of the population that is targeted with 
the therapy, including those that would refuse treatment. In the 
context of rare diseases, EU regulators expressed that it could 
not be expected to reach the level of representativeness as in 
common diseases but that agreements should be made on the 
approach of selecting the patient sample.
To ensure representativeness of the patient sample, regulators 
found that a structured research question and disease area 
specific approach to define the patient sample should be set-up 
early in the design phase of the study. Moreover, regulators 
suggested to do sample size calculations and together with 
industry and HTA representatives stated that available 
epidemiological data should be investigated to assess population 
heterogeneity and understand preference heterogeneity when 
PPS results are available. It was recognized that reaching 
representativeness is a difficult exercise and that it is “a balance 
between methodological rigor and pragmatism” (HTA2_EU). 
Diversity and representativeness should be ensured through a 
set of criteria, stratified sampling or other sampling schemes. 
According to industry and regulatory representatives, the patient 
sample should ideally cover different age groups, genders, 
cultures, ethnicities, geographical areas (continents, countries 
or regions depending on what decisions are aimed to inform), 
levels of education, time since diagnosis, stages and severities of 
disease, and treatment experiences. Also, different recruitment 
channels should be explored to reach the different types of 
patients (e.g. patient organizations and physicians). While 
industry representatives agreed on the previous requirements, 
they had differing opinions on whether “average” patients or 
expert patients should be included in the sample.
Method and Instrument Design
Method and instrument design of PPS was discussed in all 
focus groups, including the kind of information patients should 
receive when participating in PPS, instrument and question 
design, question administration, and factors influencing 
participation. Patients and caregivers had different preferences 
for surveys, interviews, and focus groups as methods to estimate 
preferences. Some LC and RA patients advocated the use of 
surveys because “one can take the time to think about it” (PA4_
IT_LC). Patients suggested that surveys should not be too long, 
involve little writing, and allow for completion from home at 
a time of their choice. Across LC and CVD patients, opinions 
differed on whether surveys should be administered online at 
home or at the hospital. LC patients that preferred interviews, 
stated that this technique allows for a more personal approach. 
Both RA and DM patients and caregivers were positive 
about the idea of group discussions, as it would allow them 
to discuss things “outside the framework” (PA1_SE_RA) and 
“because people say something and then they trigger something 
in yourself ” (CA1_UK_DM). DM participants underlined 
the importance of organizing this discussion among a small 
number of participants, as seeing people with the same suffering 
can be confronting. Local meetings for DM patients and their 
caregivers ('support groups') would be the most optimal place 
for this disease group to have focus groups. As further detailed 
in Supplementary Material V, other facilitators and barriers 
to participate in PPS related to the relevance and possible 
impact of the research, hope, encouragement of caregivers, the 
relationship with the recruiting person, self-perception and 
disease acceptance, interaction with other patients, financial 
compensation, convenience, attractiveness and feedback on 
results. Discussions with patients and caregivers also revealed 
general categories of attributes to be considered in the 
design of these studies, namely benefits, risks, price, quality, 
administration, packaging, and storage. LC and RA patients 
explained their information needs during preference studies; 
these needs included purpose and topic of the study, ethical 
review, treatment-related information, and more specifically, 
information on attributes, including the side effects, expected 
therapeutic effects, and dosage form.
Question design and patient education during PPS was 
discussed. While one industry representative stated “There's 
no reason why you can't educate a patient to understand the 
questions that are being asked” (IN4_EU), all regulators and 
HTA representatives as well as the other industry members 
found it important that questions are simple and questions are 
adapted to the patients, not the patient sample to the method. 
They believed that if the method comes with a cognitive burden 
that is too high for the patients, the method should be changed; 
moreover, patients should not be excluded because they are 
not able to understand the questions. Industry, regulatory, and 
HTA representatives expressed the need to provide patients with 
information on the study and sufficient unbiased information 
on the questions to enable patients to make choices. Overall, 
industry representatives underlined the importance of rigor, 
validity, and robustness of study design to increase acceptance 
and use of results by regulators, HTA bodies and payers. 
Regulators accentuated the importance of performing qualitative 
studies prior to quantitative studies; “good qualitative research 
is going to be incredibly important in order to get to any good 
design of quantitative preference study” (RE2_EU). Moreover, 
industry discussed that in early stages of development qualitative 
methods might be more appropriate to get some initial insights 
and to see if the product could fulfill any high unmet needs, and 
that quantitative methods could provide scientific preference 
evidence in later stages.
Organizational Considerations
Organizational considerations for PPS were discussed, 
including when to conduct these studies, financial 
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considerations, roles of stakeholders in design and conduct, 
and data management of preference data. According to 
some industry representatives, PPS should be planned early 
in the MPLC and included in the development plan to be 
conducted during pre-clinical or clinical phases. Some were 
concerned that the conduct of PPS would extend the duration 
of the development phase. HTA representatives believed these 
studies to be costly and long in duration.
The main organizational discussion point was the roles 
of stakeholders in design and conduct of PPS. According to 
industry, expert patients should be involved to ensure that 
questions are understandable, and regulators should be 
involved to ensure a rigorous design acceptable to regulators. 
HTA representatives stated clearly that they could not fund 
and conduct PPS. Both HTA and regulators expected industry 
to fund and conduct PPS in collaboration with independent 
parties like academics, physicians, patients and patient 
organizations, to overcome possible biases from industry, in 
“public-private partnerships” (HTA4_CAN) or with multiple 
companies that “could challenge each other” (HTA4_CAN). 
Regulators and HTA bodies could also be involved, but HTA 
representatives mentioned that this is challenging for them 
because of conflict of interest and because it is “out of their 
comfort zone” (HTA4_CAN). The best way to involve them 
would be through scientific advice. US regulators stated that, if 
the design of the study is appropriate, it does not matter who 
conducts the study.
On ownership of patient preference data, HTA representatives 
argued that these data should be kept in the public domain 
and should not be owned by a single company since patient 
preferences are not specific for one product; this also in order to 
avoid duplication of efforts and research fatigue within patient 
populations. Patients and caregivers believed that hospitals 
might prove trustable data storage sites. Differing opinions 
were expressed on whether ministries of health and national 
insurance houses should be responsible for managing PPS data. 
Patients underlined the importance of treating their information 
in a confidential way through anonymization. Importantly 
however, some participants spoke about the balance between 
confidentiality and “moving things forward” (PA1_UK_DM); 
confidentiality should not inhibit the possibility of feeding 
back the results to patients nor should it stand in the way of the 
development of medical products that might ultimately benefit 
them. Participants from all disease areas agreed it would be 
beneficial to share information coming forth from PPS among 
relevant stakeholders.
Use of Patient Preferences
Value of Patient Preferences
Overall, industry, regulators and HTA representatives found 
patient preferences valuable and important. An EU regulator 
stated “At the end of the day, any patient preferences are going 
to be valuable at any kind of regulatory assessment, whether 
this is pre-, during or even doing post-authorization studies” 
(RE2_EU). Some HTA representatives mentioned that current 
value measures like Quality Adjusted Life Years (QALYs) and 
Quality of Life measures did not cover the patient perspective 
sufficiently and additional measures were sometimes necessary. 
Across industry, regulators and HTA representatives it was 
expressed that currently the patient voice is mostly sought 
through direct participation of patients in discussions or though 
qualitative methods, and that quantitative PPS are not often 
submitted to regulators and HTA bodies. EU regulators and 
HTA representatives emphasized the importance of assessing 
the added value of PPS per situation. They recognized that 
assessing this value can pose a challenge: “it will probably be 
difficult to get clear guidance where you really need to do those 
studies, where you have to provide data in advance” (RE4_EU). 
Regulatory, industry and HTA representatives further discussed 
situations in which patient preferences would be of added value 
(Box 1). Overall, situations were found sensitive to patient 
preferences in certain cases of uncertainty in the benefit-risk 
profile, if assessors are not familiar with a new type of treatment 
or disease area, or when “some people like some benefits, some 
people like other benefits” (RE3_US).
Position of Patient Preferences in Industry 
Decision-Making
A cultural barrier toward the systematic use of patient preferences 
was identified by industry representatives. The cultural barrier 
was said to be caused by people in the industry not wanting 
patients to influence what they think they know best, or thinking 
these studies are not credible or robust enough compared to 
“proper science” (IN7_EU). In addition, industry representatives 
were not sure whether all authorities accept patient preference 
information. Industry representatives agreed on the importance of 
having a “process” (IN7_EU), “structure” (IN3_EU), “framework” 
(IN1_EU, IN3_EU) or “good practices” (IN1_EU) for measuring 
and using patient preferences, as these would lead to more 
robust results and easier integration. Industry representatives 
saw potential for systematic inclusion of patient preferences in 
benefit-risk assessments as there is a “new requirement under the 
ICH guideline about including patient preference in our overall 
clinical overview” (IN1_EU); referring to the 'Benefits and Risks 
Conclusions' section of the ICH M4E(R2) guidance (ICH, 2016). 
Industry, regulatory and HTA representatives further discussed 
the different potential applications of patient preferences along 
industry processes (Box 2).
Position of Patient Preferences in Regulatory 
Decision-Making
According to EU regulators, PPS are not often submitted to 
regulatory agencies in the EU and they are not systematically 
considered in decision-making regarding marketing 
authorizations. EU regulators stated that these studies 
could be requested and considered on a case-by-case basis. 
In contrast to EU regulators, US regulators named multiple 
examples of decision-making where patient preferences were 
taken into account and explained that patient preferences are 
increasingly becoming an important factor within benefit-
risk assessment, mainly for medical devices. While EU and 
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US regulators and industry representatives discussed different 
potential applications of patient preferences along regulatory 
processes (Box 3), multiple EU regulators believed benefit-
risk assessment to be the only process through which patient 
preferences can have an influence on the final decision; 
“Quite frankly, I think it can be only in the benefit-risk. That 
is where the regulators will make the decision” (RE4_EU). 
Within benefit-risk assessment, subgroup identification was 
found to be important as this would allow identification of 
subpopulations more willing than the majority to accept risks 
in order to receive certain benefits. Regulators stated that if it 
is demonstrated that a subpopulation would tolerate the risks 
associated with a certain product, that they would be willing to 
approve that product for the whole patient population, so that 
the subpopulation has the chance of receiving the treatment. 
Other patients would still be able to refuse the treatment 
in this case. Another important application mentioned by 
EU regulators was the assessment of major contribution to 
patient care. To be granted an orphan designation in Europe, 
developers may have to show that the product brings significant 
benefit, meaning a clinically relevant advantage or a major 
contribution to patient care compared with existing methods 
to treat the condition. Major contribution to patient care 
can include convenient modes of administration improving 
patient compliance, improved availability, or other arguments 
that may improve quality of life (Committee for Orphan 
Medicinal Products (COMP), 2010; European Medicines 
Agency (EMA), 2018). EU regulators mentioned they might 
request to perform PPS if major contribution to patient care 
is claimed. In the context of orphan drugs, an EU regulator 
stated “patient preference may be the main information that we 
are looking at for making our regulatory decisions”.
BOX 1 | Patient preference sensitive situations.
Situation Reason why patient preferences are valuable Source
Special disease areas and patient 
populations
Rare diseases, areas of unmet medical 
need and new disease areas
Because limited information available and limited expertise of doctors; “we don't quite know what 
we're doing” (IN7_EU).
IN, RE
Pediatric populations Because of challenges in clinical trials and disease management related to formulation and route of 
administration.
IN, RE
Chronic diseases and oncology Because of the time patients have to live with the disease. Although some found it as important 
in acute diseases, and did not think it would be valuable in well-known and well-studied common 
diseases.
IN
Diseases with a range of disease stages 
and manifestations
Because the disease heterogeneity and differences in treatment effects can cause split views between 
regulators as they may not be thinking of the same types of patients.
RE
Suspected preference heterogeneity 
and subgroups
Because patient preference studies could reveal subgroups for which the treatment is of different 
value, although regulators also mentioned this could complicate assessments.
RE, HTA
Special side and therapeutic effects
Special side effects Because of unexpected side effects or safety issues, e.g. very toxic oncology treatments. IN, RE
Novel benefits Because it is uncertain what patients think about these novel benefits. RE
Symptom relief Because symptom relief is something that can be perceived in a different way among patients, 
especially if drugs have a delayed impact on symptoms.
IN
Prolongation of life Because life prolongation of two or three months “might be considered by HTA bodies or payers as 
not so impressive” (IN3_EU), while patients can perceive this in a different way and may need to trade-
off quality versus prolongation of life.
IN
Minor modifications in quality of life Because it is difficult for evaluators to understand the impact of these minor modifications. HTA
Special types of treatments
Novel therapies Because it is uncertain what patients think about these novel technologies like precision medicine 
where it could help identify “the right patient”; “if you look at twins, identical twins. They both have the 
same disease. They are both offered the same treatment. The treatment, essentially, is going to react 
the same way with both of them but because of their different preferences one may choose it, one 
may not” (RE1_US).
RE
Treatments that preclude other 
treatments
Because the treatment would preclude the patient from getting alternative treatments in the future. RE
Availability of other treatments In some disease areas where a lot of treatments are available patient preferences were found to be 
not very valuable by regulators. In contrast, HTA representatives found patient preferences important 
in cases where alternatives are available that has different effects.
RE, HTA
Regulatory requirements Because patient preferences could become more important than those of regulators when regulatory 
requirements are “old fashioned or even limited” (IN3_EU) due to unfamiliarity with the topic. However, 
in the case of strict regulatory pathways or “routine” (IN7_EU) clinical studies and disease areas there 
is no added value of patient preferences.
IN
Borderline benefit-risk profiles Because regulators may not reach consensus on a decision due to presence of uncertainties with 
regards to clinical endpoints.
IN, RE
Borderline cost-effectiveness ratios Because the result of the assessment is unclear. HTA
HTA, health technology assessment focus group; IN, industry focus group; RE, regulatory focus group.
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Position of Patient Preferences in HTA
While HTA representatives discussed how PPS would always be 
considered when submitted, their use in assessments would be on 
a “case-by-case basis” (HTA3_EU). Their incorporation in HTA is 
uncertain since current frameworks form an operational barrier as 
they do not give weights to the different decision criteria and are 
holistic. One HTA representative mentioned that in the future it 
may be possible to incorporate all aspects in a multi-criteria decision 
analysis (MCDA). There were differing opinions on whether PPS 
should be kept separate from other processes and assessments in 
HTA. HTA representatives expressed the concern that patient 
preferences could complicate decision-making and could be 
confusing; they emphasized that use of patient preferences has to be 
practical and has to fit within their timelines. HTA representatives 
emphasized that if PPS would be submitted, the objective of 
the study and how this could facilitate, improve or complicate 
decision-making should be clear. To allow for assessment of the 
quality and appropriateness of PPS, HTA representatives thought 
BOX 2 | Potential applications of patient preferences along industry processes.
Application Value of patient preferences Source
Disease familiarization To know what the disease means to the patient. IN
Medical need assessment To understand what patients value, need, want and don't want regarding treatment options. To provide 
information on “what problem they would like us to fix” (IN7_EU) and the importance of outcomes to patients, 
impact on symptoms and survival.
IN
Understanding alternative 
treatments
To assess what treatment (medicinal products, surgery and devices) options exist for patients. RE
Go, no-go decisions To inform “go, no-go type decisions made by companies” in early development (HTA4_CAN). HTA
Scientific advice To have patients, or a mix of patients and patient experts, involved in scientific advice discussions. IN
Clinical trial design To inform clinical trial design, especially in young pediatric populations, to increase recruitment and retention of 
patients.
IN
Endpoints and patient reported 
outcomes identification
“To help determine whether the outcomes are important to patients" or even "to get a better understanding of 
a super outcome” (RE6_US).
IN, RE
Designing patient information and 
consent forms
To ameliorate presentation and content of patient information and consent forms. IN
Formulation and dosage choice To inform formulation and dosage choice, especially when there is a choice between formulations with different 
efficacies.
IN
Benefit-risk assessment To assess if the delivered benefit is meaningful to patients. IN
Subgroup identification To inform regulators of subgroups where the relevance of the benefit could be more important and to show 
“one size doesn't fit all” (IN6_EU).
IN
Submission to regulators, HTA 
bodies and payers
To include in submissions to support the evidence and value proposition in the dossier and to allow for 
discussion.
IN
Labeling To include patient preferences in labeling, reflecting what is important to patients and preventing to put black 
box warnings and taking medicines off the market too quickly.
IN
Product profile validation To assess in the post-marketing phase if the product fulfils the target product profile according to patients' 
needs, and to assess factors influencing adherence.
RE
Informing new product 
development
To inform development of new products, especially for medical devices where development is “a lot faster” 
(RE6_US).
RE
HTA, health technology assessment focus group; IN, industry focus group; RE, regulatory focus group.
BOX 3 | Potential applications of patient preferences along regulatory processes.
Application Value of patient preferences Source
Understanding the disease To improve regulators' understanding of the disease. RE
Benefit-risk assessment Patient preferences could become part of the different sections of the benefit-risk assessment and 
could influence the final decision.
IN, RE
Meaning of benefit-risk profile to patients To understand what patients think about certain benefit-risk profiles. RE
Maximum acceptable risk assessment To assess “The clinically meaningful benefit for a patient, so maximum acceptable risk to a patient” 
(RE4_US).
RE
Weighing of endpoints To explore how important different endpoints are to patients. RE
Subgroup identification To identify and understand subpopulations with different risk tolerances. RE
Major contribution to patient care 
assessment
To understand “advantage based on a major contribution, so an advantage for a patient” (RE5_EU) 
that does not relate to efficacy or safety.
RE
Post-authorization assessments To re-evaluate the product. RE
Indication expansion To support expansion of the approval to other indications. RE
IN, industry focus group; RE, regulatory focus group.
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a tool (checklist or decision tree) could be valuable. However, they 
acknowledged that assessing quality may be context-dependent, 
making it difficult to create such a tool. Ideally, the tool would allow 
for the assessment of sample and method appropriateness, validity, 
consistency and quality of data. HTA representatives further 
discussed the different potential applications of patient preferences 
along HTA processes (Box 4). HTA representatives thought patient 
preferences could be included in cost-effectiveness analyses, but 
were unsure of the mechanism to enable this other than weighing 
clinical outcomes and QALYs according to the preferences.
DiSCUSSiOn
We performed a multi-method study consisting of literature 
reviews, interviews and focus groups, to investigate how PPS 
should be designed, conducted and used in decision-making. 
The results across the different steps in the study are graphically 
summarized in Figure 2.
Design and Conduct of Patient 
Preference Studies
Five main stakeholder beliefs were identified: 1) industry and 
regulators were interested in PPS showing trade-offs between 
treatment attributes, and HTA and regulators were interested in 
what attributes patients prefer; 2) all stakeholder groups wanted 
PPS to be designed considering the research questions and 
patient population to ensure understanding of the questions to 
patients; 3) the MPLC phase was believed to influence patient 
sample requirements and the choice of the method, as the patient 
sample should be heterogeneous in early drug development stages 
where qualitative methods can be applied, and representative 
of the patient population that is targeted with the therapy in 
quantitative studies during late development; 4) collaboration 
among different stakeholders is needed in the design and 
conduct of PPS, including patients to ensure comprehensibility 
of questions to patients; and 5) results from PPS should be shared 
with relevant stakeholders to prevent duplication of efforts and 
research fatigue in patient populations, and to ultimately inform 
development of medical products.
In our previous literature review and interview papers on 
factors to consider in PPS design and conduct (van Overbeeke 
et al., 2019; Whichello et al., 2019), we identified 15 main factors 
that can influence the value of PPS and can occur along design 
and conduct of the studies: expertise, financial resources, study 
duration, ethics and good practices, patient centeredness, 
examining patient and/or other preferences, ensuring 
representativeness, matching method to research question, 
matching method to MPLC stage, validity and reliability of 
the method, cognitive burden, patient education, attribute 
development, patients' ability/willingness to participate, and 
preference heterogeneity. The focus group results confirm the 
necessity of different expertise, as also described by Wolka et al. 
(van Til and Ijzerman, 2014), the Medical Device Innovation 
Consortium (MDIC) report (MDIC, 2015), van Til et al. (2014), 
Selig (2016), and Ho et al. (2016). Moreover, these results 
give further insights on what and why collaborators should 
be involved, including patients to create a patient centered 
design, and indicate that PPS results have to be shared among 
stakeholders. These focus group results give also more insights 
into what research questions PPS should answer, moving 
beyond the previous discussion on when patient and when 
public preferences need to be sought (van Overbeeke et al., 
2019; Whichello et al., 2019), and clarifying that PPS should 
investigate preferred attributes, and trade-offs between benefits 
and risks, and between benefits and administration attributes. 
The results of the focus groups also confirm that stakeholders 
are concerned about the rigor, validity and reliability of PPS 
(MDIC, 2015; Selig, 2016; Mühlbacher et al., 2017; Janssens et 
al., 2019; Janssens et al., 2019). The necessary match between 
the research question, MPLC phase, sample and method was 
previously described in our literature and interview papers (van 
Overbeeke et al., 2019; Whichello et al., 2019) and by the FDA 
(FDA, 2016), Egbrink and Ijzerman (2014), and Gutknecht et al. 
(2016). However, the focus group results clarify what research 
questions need to be answered, what samples and methods are 
useful in what stages of the MPLC, how representativeness of the 
sample to the population can be ensured and that the method 
should be matched to the abilities of the patient population to 
reduce cognitive burden and ensure understanding of questions.
BOX 4 | Potential applications of patient preferences in HTA.
Application Value of patient preferences Source
Scientific advice To assess if activities in “development labs” (HTA4_CAN) are justified. HTA
Identification of 
endpoints
To assess which endpoints to consider in assessments. HTA
Weighing of endpoints To weigh “efficacy versus safety” (HTA3_EU) and “weigh the end points according to the preferences expressed in 
preference studies” (HTA1_EU).
HTA
Subgroup identification To understand to what subgroups “the treatment might have particular value within a much larger patient population” 
(HTA2_EU), and to understand what the uptake would be in that subgroup.
HTA
General assessment To use patient preferences in effectiveness assessments to understand the importance of the effectiveness to patients, 
leading to inclusion of the results in the general assessment of the intervention.
HTA
Cost-effectiveness 
analysis
To give a weight to clinical outcomes and QALYs, predict real-world adherence and cost-effectiveness. HTA
HTA, health technology assessment focus group; QALY, Quality Adjusted Life Year.
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Use of Patient Preference Studies
Besides the identified stakeholder beliefs, this study also gave 
insights into how patient preferences can be used in the MPLC. 
While stakeholders agree that including patient preferences in 
decision-making is valuable, the submission of PPS and the use 
of study results in decision-making are limited. Cultural and 
operational barriers seem to exist that limit their use, mainly 
among industry and HTA, as previously identified in our 
interviews (Janssens et al., 2019; Whichello et al., 2019).
Previous studies identified decision-making situations 
sensitive to patient preferences (van Overbeeke et al., 2019; 
Whichello et al., 2019), and the focus group results provide 
a rationale for why that is the case (Box 1). We can conclude 
that the value of PPS in decision-making depends on the 
sensitivity of decisions regarding medical products to patient 
preferences. Sensitivity to patient preferences can relate to the 
level of understanding and familiarity with the disease area and 
patient population, the types of therapeutic effects, the types 
of treatments, regulatory requirements, benefit-risk profiles, or 
cost-effectiveness profiles.
Four applications along the MPLC were identified that are most 
promising for the systematic integration of patient preferences 
in decision-making. First, patient preferences could be used 
in benefit-risk assessment by attaching weights to endpoints, 
identifying subpopulations with different risk tolerances, assessing 
value of products to patients, and assessing maximum acceptable 
risk. These results are supported by Jackson et al. (2019), Hollin 
et al. (2017), and Hauber et al. (2013). Second, they can be 
used in the assessment of major contribution to patient care by 
European regulators and will improve understanding the value 
of non-clinical advantages to patients. Third, patient preferences 
could be used in cost-effectiveness analysis at the HTA stage by 
weighing clinical outcomes and QALYs, and predicting real-world 
adherence. Lastly, multi-criteria decision analysis could be applied 
in HTA by weighing endpoints according to the preferences, as 
also stated by Mott (2018). On the use of patient preferences in 
HTA, the HTA representatives seemed to have different opinions 
regarding whether and how results of PPS need to be integrated. 
Kievit et al. (2017) created a six question checklist that may 
meet HTA representatives' needs for a tool to appraise PPS. In 
addition to these four applications, other important applications 
identified throughout the three steps of our multi-method study 
are assessment of disease familiarization and unmet medical 
needs during the discovery phase, identification of endpoints 
and patient relevant outcomes during clinical development, and 
informing new product development in post-marketing phases 
(MDIC, 2015; FDA, 2016; Selig, 2016; Bloom et al., 2018; van 
Overbeeke et al., 2019; Whichello et al., 2019; Stamuli et al., 2017).
Strengths and Limitations
The design of the focus group guides was informed by previous 
research, and the focus groups were able to dig deeper into topics 
on which opinions differed during interviews and topics that 
needed more explanation. Moreover, the topics for the focus group 
guides were ranked and selected with the help of the relevant 
FigURe 2 | Graphical summary of the main results from the different steps in the multi-method study. Main learnings to consider in the design and conduct of 
patient preference studies are shown in orange. Barriers to the use of patient preferences in the medical product life cycle are indicated in the red box. In green, 
the situations sensitive to patient preferences are highlighted as facilitators toward to use of patient preferences. In blue, the applications of patient preferences 
are indicated throughout the medical product life cycle. Abbreviations: HTA, health technology assessment; MCDA, multi criteria decision analysis; MPLC, medical 
product life cycle; PPS, patient preference studies.
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stakeholder groups. Overall, in the design, conduct, and analysis 
of focus groups, a structured and transparent approach was taken.
Although focus groups by nature provide subjective evidence 
that may not be generalizable to every organization or country, 
our study ensured the inclusion of diverse types of stakeholders 
to represent different perspectives. Patients, caregivers and 
physicians were recruited from different countries and in different 
disease areas, leading to broad and diverse patient and caregiver 
samples with different levels of involvement in healthcare. 
However, we noticed that most patients and caregivers that 
participated were over 60 years old and had no diploma or a high 
school diploma, making the results from patient focus groups not 
representative for younger and higher educated populations. The 
participants in other focus groups were recruited via PREFER 
contacts, possibly resulting in a sample that was more aware of 
the concept of patient preferences than the average stakeholder.
Focus groups with industry, regulators and HTA representatives 
were moderated by two researchers, of which one attended all focus 
groups. Patient focus groups were moderated by four independent 
researchers, which may have led to some variability. However, 
before the start of the patient focus groups all moderators had a 
meeting to discuss the guide in detail to minimize this variability. 
As patient focus groups were conducted in the native language 
of the patients, the materials had to be translated from English to 
these respective languages. Back-and-forth translation was used to 
ensure the meaning of the information and questions in the guides 
and surveys was consistent. Materials were corrected if the back 
translation showed a different meaning from the original.
Future efforts to improve implementation 
of Patient Preferences
The use of PPS in decision-making seems to be in a transition 
period. If we apply our results to the phases of change management 
(Barrow and Toney-Butler, 2019), we see that most stakeholders 
are going through the 'knowledge and persuasion' phases towards 
the 'decision' phase. In these early phases it is crucial to have 
change champions (i.e., players that believe in the change and 
drive the implementation further), like the FDA in the regulatory 
context and the National Institute for Health and Care Excellence 
(NICE) from the UK in HTA (FDA, 2016; NICE. NICE provides 
first scientific advice on patient preference study design, 2019). 
Through our study we identified multiple issues to be resolved 
in the preference research area. Future research should focus on 
quantifying the importance of concepts identified in this study, 
but also on when and how to use what preference exploration 
or elicitation method, how to calculate minimum sample sizes 
considering representativeness requirements for each of these 
methods, and what weight patient preferences should be given in 
decision-making. To further advance the implementation of patient 
preferences in decision-making we also believe it is crucial to pay 
attention to the 'knowledge' phase of stakeholders and to educate 
industry, regulators, HTA and payers on how PPS are conducted, 
what methods can be used and what the possible outcomes of 
PPS can be. In addition, ways to use patient preferences have to 
be further explored with educated stakeholders to optimize their 
implementation in decision-making. To advance the use of patient 
preferences in HTA and payer decision-making specifically, we 
believe country or healthcare system-specific studies are needed, as 
the implementation may be different across systems, to investigate 
how patient preferences can be incorporated in processes like cost-
effectiveness analysis and multi-criteria decision analysis.
COnCLUSiOnS
When designing and conducting PPS to inform decision-making 
in the MPLC, five key considerations need to be taken into account: 
1) preferred attributes, as well as trade-offs between benefits and 
risks, and between benefits and administration attributes should 
be investigated; 2) the design should be informed by the research 
questions and patient population; 3) the patient sample and 
method should match the MPLC phase; 4) collaboration between 
different stakeholders in needed; and 5) results from PPS should be 
shared among relevant stakeholders. Moreover, decision-situations 
sensitive to patient preferences were identified. The more sensitive a 
decision is, the more value PPS could have. While PPS are not often 
submitted to regulators and HTA bodies and their use in decision-
making is currently limited, potential applications for PPS where 
identified across industry, regulatory and HTA processes. Some of 
these applications hold the potential for systematic integration of 
patient preferences in decision-making in the MPLC. However, 
stakeholders need to be further educated on the concept of PPS 
to support efforts exploring how to optimize inclusion of patient 
preferences in decision-making.
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